Physician Focus on Parkinson's
Issue 14 (Summer 2010) - Quarterly CME Newsletter on Parkinson's Disease
To receive CME credit for this activity, please complete the post-test and evaluation below. Once submitted, a certificate will be issued within two weeks to the email address provided.
Click here to view Issue 14 online. You may also view the Patient Education Tool online here.
TO VIEW THE CASE REPORT AND VIDEO OF THE CASE OF THE CYCLING PD PATIENT, CLICK HERE.
If you have any questions, please contact intellyst® Medical Education at 720-748-8800.
Target Audience
Neurologists, NPs and PAs specializing in neurology.
Statement of Need
Parkinson’s disease (PD) is the second most common neurodegenerative disease. The mean age of onset is 61 years, but may begin as early as age 40 or less. It affects an estimated half million to one million Americans. That number is expected to double in the next 25 years as the population ages and as treatments for other diseases prolong the survival of aging adults. PD is classified as a movement disorder, because its most prominent symptoms are tremor, rigidity, slowed movements, and postural instability. However, PD also includes a wide range of non-motor symptoms, including depression, anxiety, sleep disorder, and autonomic symptoms, and these may be at least as debilitating as motor symptoms for many patients.
Learning Objectives
At the conclusion of this activity, participants should be able to:
• Discuss non-motor features of Parkinson’s disease and their impact on quality of life, including, anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders
• Describe medications available for treatment of motor symptoms of Parkinson’s disease in early and fluctuating disease as well as their side effects
• Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease modifying agents in Parkinson’s disease
Disclosures
Robert Hauser, MD (Case Study Contributor)
Gary VanderArk, MD (Independent Reviewer)
Richard Robinson (Medical Writer)
Accreditation Statement
intellyst® Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
intellyst® Medical Education designates this activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
|
|
|
| PD patients have special dietary and nutritional issues due to: |
|
| When a PD patient asks what type of exercise is best, the optimal response is: |
|
| The phenomenon of underscaling may account for: |
|
| A newly diagnosed PD patient presents to your office to discuss treatment. What issues should be raised in this visit? |
|
| Compared to MAO-B inhibitors, dopamine agonists: |
|
| AD is a 72 year old woman who has developed a right-sided tremor and slight stiffness consistent with a diagnosis of PD. Her health is otherwise good, and her cognition is excellent. Her symptoms have begun to interfere with her daily activities, including tennis. An appropriate first medication for AD might be: |
|
| GF is a 49 year old office manager with a 5-year history of PD. He is taking a dopamine agonist and an MAO-B inhibitor, plus an anxiolytic. He reports that his coworkers and spouse have begun to have difficulty understanding his speech, which has become noticeably softer, especially at the end of sentences. A possible treatment strategy would be: |
|
| ______ may improve motor skills more than ______, according to a recent randomized and blinded trial. |
|
| In the case study of patient RS presented by Dr. Hauser, physical therapy was thought to benefit the patients: |
|
Please indicate your level of agreement with the following statement, with "1" indicating reject completely, and "5" indicating accept completely:
|
| The risk of sudden sleep onset outweighs the benefit of dopaminergic agents for most PD patients early in their disease. | |
|
|
|
|
Please evaluate the activity objectives by selecting how well each has been met, with 5 indicating excellent and 1 indicating poor.
|
| Discuss non-motor features of Parkinsons disease and their impact on quality of life, including anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders | |
| Describe medications available for treatment of motor symptoms of Parkinsons disease in early and fluctuating disease as well as their side effects | |
| Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease-modifying agents in Parkinsons disease | |
Please evaluate the effectiveness of the case study by Dr. Robert Hauser, in both areas listed below, with 5 indicating excellent and 1 indicating poor.
|
| Usefulness of information presented. | |
| Objectivity/fair balance of content. | |
| Do you intend to make changes or apply this information to your practice as a result of this activity? |
|
Please explain your response to the above question:
|
Was there any commercial bias perceived in relation to this activity? If yes, please describe.
|
Is there anything you would like to communicate to the authors?
|
Suggest topics you would like to see in future activities.
|
| First Name | |
| Last Name | |
| Degree/Credentials | |
| Phone | |
| Fax | |
| Email | |
By typing your name below, this will act as your signature.
|
| Signature | |
| Date | 
|
|
|
|
|
|